 |
 |
| 9alpha,
11beta-PGF2alpha Colorimetric (EIA)
Kits |
| Assay Format |
Catalog # |
Kit Insert |
MSDS |
Assay Layout |
| 96 Well Kit |
900-012 |
|
|
|
| 5 x 96 Well Kit |
901-012 |
|
|
|
|
FOR RESEARCH PURPOSES ONLY, NOT FOR DIAGNOSTIC USE. |
 
|
Low cross reactivity to other eicosanoids
Time to Answer: 3 hours
|
9alpha, 11beta-Prostaglandin F2alpha (9alpha, 11beta-PGF2alpha)
is produced in vivo from Prostaglandin D2 by an 11-keto reductase
enzymatic pathway. 9alpha, 11beta-PGF2alpha has been shown to
have vasoconstrictor, bronchoconstrictor and platelet anti-aggregatory
activities. It also assists in the inflammatory response and regulation
of water and electrolyte excretion. Clinically, urinary 9alpha,
11beta-PGF2alpha is elevated in bronchial asthma and is being
examined as a marker for systemic mast cell disease.
 |
|
|
1. Pipet Standards and Samples in duplicate into the wells.
2. Pipet the blue Alkaline Phosphatase Conjugate followed by the yellow
Antibody into the wells and incubate.
3. Aspirate and wash the plate.
4. Pipet Substrate into the wells and incubate.
5. Pipet Stop Solution and read on a plate reader at 405 nm.
6. Calculate sample concentrations from Standard Curve.
|
| |
9alpha, 11beta-PGF2alpha
(900-012 & 901-012) |
| RANGE |
32-500,000 pg/mL
|
| SAMPLE SIZE |
100 µL |
| SAMPLES PER 96
WELL KIT |
37 in duplicate
|
| SENSITIVITY |
15.7 pg/mL
|
| 50% INTERCEPT |
2,263 pg/mL
|
| PRECISION |
6.2-12.1% Intra
7.5-13.4% Inter |
SAMPLE TYPE
recommended dilution |
culture media (1:5)
saliva (1:5)
urine (1:5)
serum (1:5)
heparin plasma (1:5)
EDTA plasma (1:5)
|
| TIME TO ANSWER |
3 Hours |
| SPECIES
SPECIFICITY |
non-specific
|
|
| Compound |
Cross Reactivity |
Compound |
Cross Reactivity |
| 9alpha, 11beta-PGF2alpha |
100% |
|
|
| <0.01%: PGE2
/ 6-keto-PGF1alpha / PGF2alpha / PGJ2
/ TXB2 / LTB4 / 13,14-dihydro-15-keto-PGF2alpha
/ 6,15-keto-13,14-dihydro-PGF1alpha |
|
+32 (0) 16
58 90 45 
+32 (0) 16
50 90 45